GlassScriptPhysician profile
Nona Kalfayan
NPI 1952354573
$4,715.46
in general payments reported to CMS, 2019-2025
26 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $322 · 2021: $1,006 · 2022: $1,079 · 2023: $491 · 2024: $453 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647 · Gift: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.38 |
| Gift | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $644.78 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $414.78 | 2022-2025 | Infuse |
| Visionary Optics LLC | $400.00 | 2025 | |
| Coopervision INC. | $242.30 | 2021-2025 | Misight Contact Lens, Paragon Crt, Onefit Contact Lens |
| Horizon Therapeutics Plc | $240.25 | 2021-2022 | |
| Maculogix, INC. | $239.23 | 2019-2020 | |
| Alcon Vision LLC | $235.67 | 2021-2025 | Total30, Tryptyr, Precision 1 |
| Sight Sciences, INC. | $217.36 | 2021-2022 | |
| Dompe US, INC. | $214.41 | 2024-2025 | Oxervate |
| Glaukos Corporation | $211.88 | 2022-2023 | |
| Topcon Healthcare, INC. | $193.05 | 2020 | |
| Optos, INC. | $171.24 | 2021 | |
| Oyster Point Pharma, INC. | $160.33 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.46 | 2021 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $124.99 | 2021 | |
| Shire North American Group INC | $124.99 | 2019 | |
| New World Medical,INC. | $119.29 | 2023 | |
| Sun Pharmaceutical Industries INC. | $118.58 | 2024 | |
| Abbvie INC. | $101.03 | 2022 | |
| Lkc Technologies, INC. | $89.53 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $63.78 | 2024-2025 | Xdemvy |
| Rxsight INC | $41.61 | 2022 | |
| Biotissue Holdings INC. | $37.93 | 2024 | |
| Allergan, INC. | $25.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nona Kalfayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.